

HCV and HIV Co-Infection in Pregnant Women Attending St. Camille Medical Centre in Ouagadougou (Burkina Faso)

J. Sempore,¹ D. Ilboudo,² A. Samandoulougou,² P. Guardo,³ P. Castronovo,³ and Salvatore Musumeci^{4*}

¹Laboratoire Saint Camille de Ouagadougou, Burkina Faso, Unité de Formation et de Recherche/SVT, Université de Ouagadougou, Burkina Faso, Italy

²Unité de Formation et de Recherche/SDS, Université de Ouagadougou, Burkina Faso, Italy

³Clinical Pathology Service, M. Ascoli-Tomaselli Hospital, Catania, Italy

⁴Department of Pharmacology, Gynecology and Obstetrics, Pediatrics, University of Sassari and Institute of Population Genetics, CNR, Alghero (SS), Italy

Five hundred and forty-seven pregnant women with less than 32 weeks of amenorrhoea, attending an antenatal clinic of St. Camille Medical Centre (SCMC) of Ouagadougou were enrolled for a hepatitis C virus (HCV) and HIV co-infection study. Fifty-eight (10.6%) were HIV positive and 18 (3.3%) were anti-HCV positive. Only seven pregnant women (i.e., 1.3%) had a documented HIV and HCV co-infection. HCV-RNA was found in 5 out of 18 (27.8%) patients, who had anti-HCV antibodies. The genotype analysis of these five patients showed that two were of 1b whereas three were of 2a genotype. Mother-to-infant transmission of the same HCV genotype (2a) was documented in only one case. High 1b prevalence has been reported in other parts of Africa, while 2a is the prevalent genotype (60%) in Burkina Faso. This genotype has a higher response rate to treatment. Serum transaminases were normal, also in presence of HCV-RNA. The higher than expected rate of co-infection in Burkina Faso seems to demonstrate a correlation between these two infections, which could influence the evolution of HIV and HCV diseases.

J. Med. Virol. 00:1–5, 2004.

© 2004 Wiley-Liss, Inc.

KEY WORDS: HCV; HIV; co-infection; pregnancy; Burkina Faso

The infection becomes chronic in about 85% of individuals and 20% of them develop severe complications such as cirrhosis [Bismuth et al., 1992] and hepatocellular carcinoma [Di Bisceglie, 1997]. In Africa more than 30 million people could be infected and 6–12 million could be chronic carriers [Madhava et al., 2002]. In Burkina Faso the frequency of anti-HCV among blood donors is about 2.5% [Nicot et al., 1997], whereas in other parts of Africa anti-HCV prevalence varies from 2% to 15.9% with a zone of high endemicity in Central Africa [Madhava et al., 2002]. HIV infected (7.2%) African population lives in Burkina Faso, where 8% of pregnant women are HIV positive [Ilboudo et al., 2003]. Since HCV shares the same transmission routes as HIV, co-infection with these two viruses could be frequent [Cropley and Main, 2000]. For example, approximately one third of HIV positive subjects in USA are also HCV positive and the co-infection is associated with a higher rate of HCV viraemia [Bonacini and Puoti, 2000; Brau et al., 2002]. It has to be stressed that in USA heterosexual transmission appears to be less common and that co-infection is mainly detected in intravenous drug users with some recent concerns regarding higher seroprevalence level in men who have sex with men. If, on one hand, triple drug therapy manages to control HIV infection nowadays, on the other hand, it is imperative to know the impact of HCV infection on the exposed populations as well as the possible associated morbidity. Moreover, in all HCV and HIV co-infected women, the infection is transmitted vertically from mother to infant

INTRODUCTION

Whereas the epidemiology of hepatitis B (HBV) and HIV is well known in sub-Saharan countries [Kiire, 1996], the epidemiology of the hepatitis C virus (HCV) is hardly documented [Sarkodie et al., 2001]. The number of individuals infected by HCV worldwide is estimated to be over 170 million [Cohen, 1999; Leyssen et al., 2000].

*Correspondence to: Prof. Salvatore Musumeci, Department of Pharmacology, Gynaecology/Obstetrics, Paediatrics, University of Sassari, Viale San Pietro 43B, 07100 Sassari, Italy.
E-mail: smusmec@tiscalinet.it; smusmec@dipchi.unict.it

Accepted 20 September 2004

DOI 10.1002/jmv.00000

Published online in Wiley InterScience
(www.interscience.wiley.com)

[Gibb et al., 2000]. The influence of HIV seropositivity on the risk of HCV transmission ranges from 3% to 20%, when the mother is either seronegative or HIV seropositive [Granovsky et al., 1998]. The prevalence of anti-HCV among pregnant women is 0.2%–7% in Africa; however, the frequency of anti-HCV positive pregnant women, the rate of co-infection, the influence of HIV on HCV, and vice versa are unknown in Burkina Faso.

The goal of this study was to specify the prevalence of HIV and HCV pregnant women attending the St. Camille Medical Centre (SCMC) of Ouagadougou (Burkina Faso) and to establish the rate of co-infection and vertical transmission in this area.

PATIENTS AND METHODS

Patients

Out of 3,314 pregnant women, who required prenatal attention at the antenatal clinic at the SCMC of Ouagadougou during the period from December 10, 2001 to July 10, 2002, we selected randomly 547 (16.5%) pregnant patients aged 18–44 years (mean age 25.9 ± 5.8). All these patients had less than 32 weeks of amenorrhoea at the time of recruitment. All pregnant mothers, applying to this institution, were offered a combined HCV and HIV test during the 7 months of this study. Each patient signed an informed consent form before being bled; the study was also approved by the Ethics Committee of the CMSC. All the selected patients were informed confidentially of the results of the present study. The acceptance was high (99%) and the examined sample 547/3314 (16.5%) was sufficiently representative; therefore, the results of this study may be considered an unbiased seroprevalence of HCV and HIV in the SCMC. HIV positive mothers were visited and their blood samples were collected for CD4 measurement. Antiretroviral therapy and a nevirapine protocol were offered to all the HIV positive mothers to prevent mother-to-infant transmission.

Methods

Blood samples were collected in EDTA tubes and centrifuged at 3,000 rpm for 10 min. Plasma was separated and frozen at -40°C . An anti-HIV antibodies test was carried out in 547 women by using the Biorad^{Q1}-Genie II Rapid Test. All positive samples were doubly tested by enzyme immunoassay (EIA), using the Abbott IMX System, in order to confirm the HIV positivity. Anti-HCV antibodies were measured in all samples by an EIA technique (Radim House, Italy) by using a micro plaque spectrophotometer reader by Sirio S (Seac, Italy); a confirmatory test was repeated in samples that were positive to the anti-HCV test performed by INNO-LIA HCV Ab III (Innogenetics, Belgium). Samples that were positive when tested by EIA and negative when tested by INNO-LIA HCV Ab III were assumed to be false positives. Liver function tests (transaminases, bilirubin) were performed in the anti-HCV positive mothers. HCV-RNA was measured through the RT-PCR HCV-RNA

Amplicor test (Roche, Switzerland) in those samples that had been confirmed to be anti-HCV positive; the genotypes were also determined by the Trugene HCV 5'NC genotyping test (Visible Genetics, USA). The characteristics (age, work, social status, marriage, number of previous pregnancy) of women were collected by a nurse with informed consent.

If the women knew their HIV status from previous medical consultation, they were asked to provide all documentation about the mode of infection. The HIV positive women were enrolled to the Prévention De La TransmissionMère–EnfantDuVIH/SIDA(PTME) program adopted by SCMC and the newborns were submitted to the nevirapine protocol [OMS, 2001]. A blood sample was collected from the newborns of women, who turned out to be positive to the INNO LIA HCV Ab III test 2 days after birth to determine HCV-RNA as well as to compare the HCV genotype of both mother and infant. Children of anti-HCV positive mothers were tested at 6 months for transaminase and anti-HCV determinations, while children of HIV or HCV/HIV positive mothers were monitored for a period of 18 months.

RESULTS

The mean age of the women studied in the present work was 25.9 ± 5.8 years (range: 18–44 years). The distribution for each age class was: 140 (25.6%), aged below 20 years; 322 (58.9%), aged between 20 and 30 years; 85 (15.5%) aged above 30 years.

Fifty-eight (10.6%) women were HIV positive and 28 (5.1%) HCV positive to the anti-HCV EIA test. Only 18/28 (3.3%), who were positive for the anti-HCV EIA test were also positive by INNO-LIA HCV Ab III test (see Table I). HIV and HCV co-infection was documented (rate of co-infection 1.3%) in seven pregnant women only. This value is higher than the expected rate of co-infection, which is estimated to be 0.348 if the two infections (HIV and HCV) are independent. The percentage of false positives ranged from 38% to 29% in the different classes of age (<20, 20–30, >30 years old); however, this difference was not statistically significant ($\chi^2 = 0.044$, $P = 0.978$).

The mean age of confirmed HCV positive women was 25.1 years and that of HIV positive women 28.9 years. The ages did not differ significantly from that of women, who were both HCV and HIV negative. Other characteristics of pregnant women in relation to their serological status are reported in Table II. Mothers 543/547 (99.3%) were married, 246/547 (45.0%) had received at least one blood transfusion during their life;

TABLE I. Anti-HCV and Anti-HIV in 547 Pregnant Women in Ouagadougou

| Serological tests | EIA positive | INNO-LIA confirmed | Percentage |
|---------------------|--------------|--------------------|------------|
| Anti-HCV | 28 | 18 | 3.3 |
| Anti-HIV | 58 | | 10.6 |
| Anti-HCV + Anti-HIV | 9 | 7 | 1.3 |

TABLE II. Characteristics of Studied Women at the Antenatal Clinic of St. Camille Medical Centre (SCMC)

| | HCV positive n = 18 (%) | HIV positive n = 58 (%) | HCV/HIV positive n = 7 (%) | HCV/HIV negative n = 464 (%) | Total 547 |
|--------------------|----------------------------|----------------------------|-------------------------------|---------------------------------|-----------|
| Own home work | 16 (88) | 52 (90) | 1 (14) | 414 (89) | 483 |
| Out office work | 2 (11) | 6 (10) | 6 (86)* | 50 (11) | 64 |
| Married | 18 (100) | 58 (100) | 7 (100) | 460 (99) | 543 |
| Not married | — | — | — | 4 (0.8) | 4 |
| Previous pregnancy | 13 (72) | 40 (69) | 7 (100) | 330 (71) | 390 |

* $\chi^2 = 30.159, P < 0.0001$.

none of them reported sexual intercourse at risk, 483/547 (88.3%) worked at home, and 390/547 (71.3%) had previous pregnancies. Only 1/7(14.3%) HCV/HIV positive women were housekeeper (see Table II).

HCV-RNA was found in 5/18 (27.8%) women with anti-HCV. All HCV-RNA positive mothers were HIV negative. The genotype analysis showed that two were 1b and three were 2a genotype (see Table IV^{Q2}). Vertical transmission of HCV was documented and the genotype 2a was also isolated in the second day of life in both mother and infant in one case only.

The liver function tests were negative in all anti-HCV positive mothers and as was the case in HCV-RNA positive mothers. The children of anti-HCV positive mothers had normal liver function tests, when tested at 6 and 12 months. Also, in the infant where vertical HCV transmission occurred, the liver function tests were negative and HCV-RNA was no longer detected in the serum, 6 and 12 months after birth. No HIV vertical transmission was detected in any of the children who were being treated according to the nevirapine protocol.

DISCUSSION

The frequency of HIV in pregnant women in Ouagadougou is higher (10.6% vs. 7.1%) than that of the overall population living in Burkina Faso. Also, the frequency of anti-HCV is higher (3.3% vs. 2.5%) than that reported for blood donors. Co-infection with HIV and HCV affects 1.3% of the pregnant women investigated in the present study; this value is lower than that found (3%) in a similar study conducted in Spanish pregnant women [Munoz-Almagro et al., 2002]. USA veterans (many of whom were using drug during the Vietnam war and were exposed to infection), currently living in New York, have a co-infection rate of 24.8% [Brau et al., 2002]. These differences point out the different mode of transmission between veterans and pregnant women, and also among pregnant women from different countries. The prevalence of anti-HCV in Burkina Faso is relatively high if compared with analogous studies carried out for the entire population of African countries such as Somalia 0.6% [Nur et al., 2000], Maroc 1% [Cacoub et al., 2000], Eritrea 1.4% [Ghebrekidan et al., 1998]. Nevertheless, studies in other parts of Africa report higher frequencies in Egypt [Arthur et al., 1997], in Gabon [Delaporte et al., 1994], and even higher (>10%) in Burundi [Ntakarutimana et al., 1995] and in Kenya [Ntakarutimana et al., 1995]. The variable frequency of

anti-HCV in different African countries unexpectedly corresponds to the unusual association between HCV and HIV in Africa (see Table III^{Q3}).

A noteworthy result is the low percentage of HCV-RNA (5/18, 27.8%) among anti-HCV positive women; in fact in both Europe and USA more than 80% of anti-HCV positive women show HCV-RNA. This seemingly anomalous result may be accounted for by the low replication of 2a genotype, which is prevalent in Burkina Faso.

The difference between expected versus observed HIV and HCV infected individuals suggests a different mechanism of transmission. In fact, in our study the ratio between HIV infected woman and the HCV infected group is 7/18 (38.9%), which is significantly higher ($P = 0.09$) than the ratio between HCV infected women and the HIV infected group 7/58 (12.1%). The high HIV/HCV co-infection rate among the pregnant women being followed by the SCMC, which is still lower than that reported for Western countries [Bonacini and Puoti, 2000; Cropley and Main, 2000; Brau et al., 2002], suggests different modalities of transmission of these pathologies: sexual and through blood transfusions, reusable needles, traditional healers, or medical and surgical interventions. When the parenteral route prevails (as, for example, in Maroc, Egypt, and Gabon) the probability to contract HCV is larger, even though the parenteral route is clearly a potential one of the HIV transmission. On the contrary, when the transmission way is prevalently related to sex, the probability to acquire HCV is lesser than the probability to acquire HIV. In fact countries, such as Kenya and Burkina Faso, that have a higher HIV infection prevalence also have a relatively lower estimated HCV prevalence.

The conclusion that in Ethiopia anti-HCV prevalence does not differ between HIV negative sex workers and women population [Munoz-Almagro et al., 2002], is in sharp contrast with the important role of sexual transmission of HCV in these populations. In fact, an individual may first acquire HIV sexually and then be infected with HCV through unsafe medical practices, traditional healers, when treated for an HIV-related illness. Although sexual transmission rates are far from well documented in developing countries, in this part of Africa the sexual transmission of HCV seems infrequent and less efficient [MacDonald et al., 1996].

The frequency of mother-to-infant HCV transmission, reported in the literature ranges from 4% to 12%; is 3.8 times higher in the case of co-infection with HIV, which is characterized by a mother with very high HCV

viremia [Conte et al., 2000]. The transmission rate does not seem to be related to the viral genotype: all our HCV-RNA positive mothers were HIV negative. The role of the mode of delivery remains controversial. Some authors claim that the mode of delivery does not play any role in the transmission [Resti, 1999], while others claim that Caesarean delivery could have a protective effect [Conte et al., 2000]. The present study shows that out of the anti-HCV positive 18 mothers only five had a Caesarean delivery and out of these only one was HCV-RNA positive. Also, the role played by breast-feeding, which is of vital importance in poor countries such as Burkina Faso, is not entirely clear. Studies carried out in other parts of Africa support the high genetic diversity of 1 and 2 HCV genotypes [Jeannel et al., 1998] and indicate that type 2 slightly prevails over type 1 (59% vs. 41%). In fact in Burkina Faso the contribution of HCV to liver disease does not seem as severe as in other parts of Africa. In these countries blood transfusion together with traditional healers and reusable needles are frequent routes of transmission within the urban population [Halim et al., 2001]. In Burkina Faso, the HCV virus shows a low pathogenicity both in the overall population and in the group of pregnant women, and the prevalent genotype is confined to 2a, known for its higher response rate to treatment [Pawlotsky, 2003].

We do not know the influence of HIV on the evolution of HCV and vice versa, but the high rate of co-infection in Burkina Faso (1.3%) demonstrates a correlation between these two viral infections which could influence the morbidity and mortality [Tedaldi et al., 2003].

ACKNOWLEDGMENTS

The authors thank Dr. Vito LaTora for helpful discussion and Dr. Michael Whalen for his precious help in editing the article.

REFERENCES

- Arthur RR, Hassan NF, Abdallah MY, el-Sharkawy MS, Saad MD, Hackbart BG, Imam IZ. 1997. Hepatitis C antibody prevalence in blood donors in different governorates in Egypt. *Trans R Soc Trop Med Hyg* 91:271–274.
- Bismuth H, Samuel D, Castaing D, Adam R, Chiche L, Johann M, Azoulay D, Farges O, Feray C, Rucay P. 1992. The Paul Brousse liver transplant series 1989 to 1992: New trends in the last four years. *Clin Transplants* XX^{Q4}:161–166.
- Bonacini M, Puoti M. 2000. Hepatitis C in patients with human immunodeficiency virus infection: Diagnosis, natural history, meta-analysis of sexual and vertical transmission, and therapeutic issues. *Arch Intern Med* 160:3365–3373.
- Brau N, Bini EJ, Shahidi A, Aytaman A, Xiao P, Stancic S, Eng R, Brown ST, Paronetto F. 2002. Prevalence of hepatitis C and co-infection with HIV among United States veterans in the New York City metropolitan area. *Am J Gastroenterol* 97:2071–2078.
- Cacoub P, Ohayon V, Sekkat S, Dumont B, Sbai A. 2000. Étude épidémiologique et virologique de l'infection par le virus C au Maroc. *Gastroentrol Clin Biol* 24:169.
- Cohen J. 1999. The scientific challenge of hepatitis C. *Science* 285:26–30.
- Conte D, Fraquelli M, Prati D, Colucci A, Miniola E. 2000. Prevalence and clinical course of chronic hepatitis C virus infection and rate HCV, vertical transmission in a cohort of 15250 pregnant women. *Hepatology* 31:751–755.
- Cropley I, Main J. 2000. Hepatitis C virus infection: Co-infection with HIV and HBV. *Res-Clin Gastrentérol* 14:265–275.
- Delaporte E, Froment A, Dazza MC, Henzel D, Larouze B. 1994. Hepatitis C in remote populations of southern Cameroon. *Ann Trop Med Parasitol* 88:97–98.
- Di Bisceglie AM. 1997. Hepatitis C and hepatocellular carcinoma. *Hepatology* 26:34S–38S.
- Ghebrekidan H, Cox S, Wahren B, Grandien M. 1998. Prevalence of infection with HIV, hepatitis B and C viruses, in four high risk groups in Eritrea. *Clin Diagn Virol* 9:29–35.
- Gibb DM, Goodall RL, Dunn DF, Healy M, Neave P, Cafferkey M, Burler K. 2000. Mother to child transmission of hepatitis C virus: Evidence for preventable peripartum transmission. *Lancet* 356:904–907.
- Granovsky MO, Minkoff HL, Tess BH, Waters D, Hatzakis A, Devoid DE, Landesman SH, Rubinstein A, Di Bisceglie AM, Goedert JJ. 1998. Hepatitis C virus infection in the mothers and infants cohort study. *Pediatrics* 102:355–359.
- Halim NK, Madukwe U, Saheb BD, Airaui LU. 2001. Hepatitis B surface antigen and antibody to hepatitis C virus among accident and emergency patients. *East Afr Med J* 78:480–483.
- Iboudo D, Sawadogo A, Simpore J. 2003. Hepatitis C and HIV co-infection in pregnant women, Ouagadougou (Burkina Faso). *Med et Malad Infect* 33:276–279.
- Jeannel D, Fretz C, Traore Y, Kohdjo N, Bigot A, Pe Gamy E, Jourdan G, Kourouma K, Maertens G, Fumoux F, Fournel JJ, Stuyver L. 1998. Evidence for high genetic diversity and long-term endemicity of hepatitis C virus genotypes 1 and 2 in West Africa. *J Med Virol* 55:92–97.
- Kiire CF. 1996. The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa: A view from tropical and subtropical Africa. *Gut* 38:S5–S12.
- Leysen P, De Clercq E, Neyts J. 2000. Perspectives for the treatment of infections with Flaviridae. *Clin Microbiol Rev* 13:67–82.
- MacDonald M, Croft N, Kaldor J. 1996. Transmission of hepatitis C virus: Rates, routes and cofactors. *Epidemiologic Rev* 18:137–148.
- Madhava V, Burgess C, Drucker E. 2002. Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. *Lancet Infect Dis* 2:293–302.
- Munoz-Almagro C, Juncosa T, Fortuny C, Guillen JJ, Gonzalez-Cuevas A, Latorre C. 2002. Prevalence of hepatitis C virus in pregnant women and vertical transmission. *Med Clin (Barc)* 118:452–454.
- Nicot T, Roget S, Denis F. 1997. Épidémiologie de l'hépatite C en Afrique. *Gastroentrol Clin Biol* XX^{Q5}:596–606.
- Ntakarutimana V, Delaporte E, Pellet D, Demedts P, Scharpe S. 1995. Seroprévalence du virus de l'hépatite C parmi les personnes fréquentant les service se soin au. *Burundi A Soc Belg Med Trop* XX^{Q6}:283–290.
- Nur YA, Groen J, Elmi AM, Ott A, Osterhaus AD. 2000. Prevalence of serum antibodies against bloodborne and sexually transmitted agents in selected groups in Somalia. *Epidemiol Infect* 124:137–141.
- Organisation Mondiale de la Santé (OMS). 2001. Prevention of mother-to-child transmission of HIV: Selection and use of nevirapine. Technical Notes.
- Pawlotsky JM. 2003. Hepatitis C virus genetic variability: pathogenic and clinical implications. *Clin Liver Dis* 7:45–66.
- Resti M. 1999. Mother-to-infant transmission of hepatitis C virus. *Ital J Gastroenterol Hepatol* 31:489–493.
- Sarkodie F, Adarkwa M, Adu-Sarkodie Y, Candotti D, Acheampong JW, Allain JP. 2001. Screening for viral markers in volunteer and replacement blood donors in West Africa. *Vox Sang* 80:142–147.
- Tedaldi EM, Baker RK, Moorman AC, Alzola CF, Furrer J, McCabe RE, Wood KC, Holmberg SD. 2003. HIV outpatient study (HOPS) investigators. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. *Clin Infect Dis* 36:363–367.

Q1: Au: Please provide the complete location for all the manufacturers given.

Q2: Au: Please provide Table 4.

Q3: Au: Please provide Table 3.

Q4: Au: Please provide the volume no.

Q5: Au: Please provide the volume no.

Q6: Au: Please provide the volume no.





WILEY

Publishers Since 1807

111 RIVER STREET, HOBOKEN, NJ 07030

*****IMMEDIATE RESPONSE REQUIRED*****

Please follow these instructions to avoid delay of publication.

READ PROOFS CAREFULLY

- This will be your only chance to review these proofs.
- Please note that the volume and page numbers shown on the proofs are for position only.

ANSWER ALL QUERIES ON PROOFS (Queries for you to answer are attached as the last page of your proof.)

- Mark all corrections directly on the proofs. Note that excessive author alterations may ultimately result in delay of publication and extra costs may be charged to you.

CHECK FIGURES AND TABLES CAREFULLY (Color figures will be sent under separate cover.)

- Check size, numbering, and orientation of figures.
- All images in the PDF are downsampled (reduced to lower resolution and file size) to facilitate Internet delivery. These images will appear at higher resolution and sharpness in the printed article.
- Review figure legends to ensure that they are complete.
- Check all tables. Review layout, title, and footnotes.

COMPLETE REPRINT ORDER FORM

- Fill out the attached reprint order form. It is important to return the form even if you are not ordering reprints. You may, if you wish, pay for the reprints with a credit card. Reprints will be mailed only after your article appears in print. This is the most opportune time to order reprints. If you wait until after your article comes off press, the reprints will be considerably more expensive.

RETURN

- PROOFS**
 REPRINT ORDER FORM
 CTA (If you have not already signed one)

RETURN WITHIN 48 HOURS OF RECEIPT VIA FAX TO Lori-Marie Hamilton at 937-885-3289

QUESTIONS?

Lori-Marie Hamilton, Production Editor

Phone: 937-885-3289

E-mail: lorimarieh@woh.rr.com

Refer to journal acronym and article production number

(i.e., JMV 00-001 for *Journal of Medical Virology* ms 00-001).

COPYRIGHT TRANSFER AGREEMENT

Date:

Production/Contribution

To:

ID# _____

Publisher/Editorial office use only

Re: Manuscript entitled _____ (the "Contribution")
_____ (the "Journal")
for publication in _____
published by Wiley-Liss, Inc., a subsidiary of John Wiley & Sons, Inc. ("Wiley").

Dear Contributor(s):

Thank you for submitting your Contribution for publication. In order to expedite the publishing process and enable Wiley to disseminate your work to the fullest extent, we need to have this Copyright Transfer Agreement signed and returned to us as soon as possible. If the Contribution is not accepted for publication this Agreement shall be null and void.

A. COPYRIGHT

1. The Contributor assigns to Wiley, during the full term of copyright and any extensions or renewals of that term, all copyright in and to the Contribution, including but not limited to the right to publish, republish, transmit, sell, distribute and otherwise use the Contribution and the material contained therein in electronic and print editions of the Journal and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so.
2. Reproduction, posting, transmission or other distribution or use of the Contribution or any material contained therein, in any medium as permitted hereunder, requires a citation to the Journal and an appropriate credit to Wiley as Publisher, suitable in form and content as follows: (Title of Article, Author, Journal Title and Volume/Issue Copyright © [year] Wiley-Liss, Inc. or copyright owner as specified in the Journal.)

B. RETAINED RIGHTS

Notwithstanding the above, the Contributor or, if applicable, the Contributor's Employer, retains all proprietary rights other than copyright, such as patent rights, in any process, procedure or article of manufacture described in the Contribution, and the right to make oral presentations of material from the Contribution.

C. OTHER RIGHTS OF CONTRIBUTOR

Wiley grants back to the Contributor the following:

1. The right to share with colleagues print or electronic "preprints" of the unpublished Contribution, in form and content as accepted by Wiley for publication in the Journal. Such preprints may be posted as electronic files on the Contributor's own website for personal or professional use, or on the Contributor's internal university or corporate networks/intranet, or secure external website at the Contributor's institution, but not for commercial sale or for any systematic external distribution by a third party (e.g., a listserv or database connected to a public access server). Prior to publication, the Contributor must include the following notice on the preprint: "This is a preprint of an article accepted for publication in [Journal title] © copyright (year) (copyright owner as specified in the Journal)". After publication of the Contribution by Wiley, the preprint notice should be amended to read as follows: "This is a preprint of an article published in [include the complete citation information for the final version of the Contribution as published in the print edition of the Journal]", and should provide an electronic link to the Journal's WWW site, located at the following Wiley URL: <http://www.interscience.Wiley.com/>. The Contributor agrees not to update the preprint or replace it with the published version of the Contribution.

2. The right, without charge, to photocopy or to transmit online or to download, print out and distribute to a colleague a copy of the published Contribution in whole or in part, for the Contributor's personal or professional use, for the advancement of scholarly or scientific research or study, or for corporate informational purposes in accordance with Paragraph D.2 below.
3. The right to republish, without charge, in print format, all or part of the material from the published Contribution in a book written or edited by the Contributor.
4. The right to use selected figures and tables, and selected text (up to 250 words, exclusive of the abstract) from the Contribution, for the Contributor's own teaching purposes, or for incorporation within another work by the Contributor that is made part of an edited work published (in print or electronic format) by a third party, or for presentation in electronic format on an internal computer network or external website of the Contributor or the Contributor's employer.
5. The right to include the Contribution in a compilation for classroom use (course packs) to be distributed to students at the Contributor's institution free of charge or to be stored in electronic format in datarooms for access by students at the Contributor's institution as part of their course work (sometimes called "electronic reserve rooms") and for in-house training programs at the Contributor's employer.

D. CONTRIBUTIONS OWNED BY EMPLOYER

1. If the Contribution was written by the Contributor in the course of the Contributor's employment (as a "work-made-for-hire" in the course of employment), the Contribution is owned by the company/employer which must sign this Agreement (in addition to the Contributor's signature), in the space provided below. In such case, the company/employer hereby assigns to Wiley, during the full term of copyright, all copyright in and to the Contribution for the full term of copyright throughout the world as specified in paragraph A above.
2. In addition to the rights specified as retained in paragraph B above and the rights granted back to the Contributor pursuant to paragraph C above, Wiley hereby grants back, without charge, to such company/employer, its subsidiaries and divisions, the right to make copies of and distribute the published Contribution internally in print format or electronically on the Company's internal network. Upon payment of the Publisher's reprint fee, the institution may distribute (but not resell) print copies of the published Contribution externally. Although copies so made shall not be available for individual re-sale, they may be included by the company/employer as part of an information package included with software or other products offered for sale or license. Posting of the published Contribution by the institution on a public access website may only be done with Wiley's written permission, and payment of any applicable fee(s).

E. GOVERNMENT CONTRACTS

In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government Employees: see note at end).

F. COPYRIGHT NOTICE

The Contributor and the company/employer agree that any and all copies of the Contribution or any part thereof distributed or posted by them in print or electronic format as permitted herein will include the notice of copyright as stipulated in the Journal and a full citation to the Journal as published by Wiley.

G. CONTRIBUTOR'S REPRESENTATIONS

The Contributor represents that the Contribution is the Contributor's original work. If the Contribution was prepared jointly, the Contributor agrees to inform the co-Contributors of the terms of this Agreement and to obtain their signature to this Agreement or their written permission to sign on their behalf. The Contribution is submitted only to this Journal and has not been published before, except for "preprints" as permitted above. (If excerpts from copyrighted works owned by third parties are included, the Contributor will obtain written permission from the copyright owners for all uses as set forth in Wiley's permissions form or in the Journal's Instructions for Contributors, and show credit to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous or unlawful statements, does not infringe on the rights or privacy of others, or contain material or instructions that might cause harm or injury.

CHECK ONE:

Contributor-owned work

Contributor's signature

Date

Type or print name and title

Co-contributor's signature

Date

Type or print name and title

ATTACH ADDITIONAL SIGNATURE PAGE AS NECESSARY

Company/Institution-owned work
(made-for-hire in the
course of employment)

Company or Institution (Employer-for-Hire)

Date

Authorized signature of Employer

Date

U.S. Government work

Note to U.S. Government Employees

A Contribution prepared by a U.S. federal government employee as part of the employee's official duties, or which is an official U.S. Government publication is called a "U.S. Government work," and is in the public domain in the United States. In such case, the employee may cross out Paragraph A.1 but must sign and return this Agreement. If the Contribution was not prepared as part of the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work.

U.K. Government work (Crown Copyright)

Note to U.K. Government Employees

The rights in a Contribution prepared by an employee of a U.K. government department, agency or other Crown body as part of his/her official duties, or which is an official government publication, belong to the Crown. In such case, the Publisher will forward the relevant form to the Employee for signature.



WILEY

Publishers Since 1807

THE JOURNAL OF MEDICAL VIROLOGY

Telephone Number:

• Facsimile Number:

To: Ms. Lori-Marie Hamilton

Fax: 937-885-3289

From: Dr.

Date: _____

Re: *Journal of Medical Virology, ms #*

Dear Ms. Hamilton,

Attached please find corrections to ms# _____. Please contact me should you have any difficulty reading this fax at the numbers listed below.

Office phone:

Email:

Fax:

Lab phone:

I will return color figure proofs (if applicable) once I have checked them for accuracy.

Thank you,

Dr.

E-proofing feedback comments:



WILEY

Publishers Since 1807

REPRINT BILLING DEPARTMENT - 111 RIVER STREET - HOBOKEN, NJ 07030

PHONE: (201) 748-8789; FAX: (201) 748-6326

E-MAIL: reprints@wiley.com

PREPUBLICATION REPRINT ORDER FORM

Please complete this form even if you are not ordering reprints. This form **MUST** be returned with your corrected proofs and original manuscript. Your reprints will be shipped approximately 4 weeks after publication. Reprints ordered after printing will be substantially more expensive.

JOURNAL Journal of Medical Virology VOLUME _____ ISSUE _____

TITLE OF MANUSCRIPT _____

MS. NO. _____ NO. OF PAGES _____ AUTHOR(S) _____

| No. of Pages | 100 Reprints | 200 Reprints | 300 Reprints | 400 Reprints | 500 Reprints |
|--------------|--------------|--------------|--------------|--------------|--------------|
| | \$ | \$ | \$ | \$ | \$ |
| 1-4 | 336 | 501 | 694 | 890 | 1052 |
| 5-8 | 469 | 703 | 987 | 1251 | 1477 |
| 9-12 | 594 | 923 | 1234 | 1565 | 1850 |
| 13-16 | 714 | 1156 | 1527 | 1901 | 2273 |
| 17-20 | 794 | 1340 | 1775 | 2212 | 2648 |
| 21-24 | 911 | 1529 | 2031 | 2536 | 3037 |
| 25-28 | 1004 | 1707 | 2267 | 2828 | 3388 |
| 29-32 | 1108 | 1894 | 2515 | 3135 | 3755 |
| 33-36 | 1219 | 2092 | 2773 | 3456 | 4143 |
| 37-40 | 1329 | 2290 | 3033 | 3776 | 4528 |

****REPRINTS ARE ONLY AVAILABLE IN LOTS OF 100. IF YOU WISH TO ORDER MORE THAN 500 REPRINTS, PLEASE CONTACT OUR REPRINTS DEPARTMENT AT (201) 748-8789 FOR A PRICE QUOTE.**

Please send me _____ reprints of the above article at \$ _____

Please add appropriate State and Local Tax (Tax Exempt No. _____) \$ _____
for United States orders only.

Please add 5% Postage and Handling \$ _____

TOTAL AMOUNT OF ORDER** \$ _____

***International orders must be paid in currency and drawn on a U.S. bank*

Please check one: Check enclosed Bill me Credit Card

If credit card order, charge to: American Express Visa MasterCard

Credit Card No _____ Signature _____ Exp. Date _____

BILL TO:

Name _____

Institution _____

Address _____

SHIP TO: (Please, no P.O. Box numbers)

Name _____

Institution _____

Address _____

Purchase Order No. _____

Phone _____ Fax _____

E-mail _____

Softproofing for advanced Adobe Acrobat Users - NOTES tool

NOTE: ADOBE READER FROM THE INTERNET DOES NOT CONTAIN THE NOTES TOOL USED IN THIS PROCEDURE.

Acrobat annotation tools can be very useful for indicating changes to the PDF proof of your article. By using Acrobat annotation tools, a full digital pathway can be maintained for your page proofs.

The NOTES annotation tool can be used with either Adobe Acrobat 3.0x or Adobe Acrobat 4.0. Other annotation tools are also available in Acrobat 4.0, but this instruction sheet will concentrate on how to use the NOTES tool. Acrobat Reader, the free Internet download software from Adobe, DOES NOT contain the NOTES tool. In order to softproof using the NOTES tool you must have the full software suite Adobe Acrobat Exchange 3.0x or Adobe Acrobat 4.0 installed on your computer.

Steps for Softproofing using Adobe Acrobat NOTES tool:

1. Open the PDF page proof of your article using either Adobe Acrobat Exchange 3.0x or Adobe Acrobat 4.0. Proof your article on-screen or print a copy for markup of changes.
2. Go to File/Preferences/Annotations (in Acrobat 4.0) or File/Preferences/Notes (in Acrobat 3.0) and enter your name into the "default user" or "author" field. Also, set the font size at 9 or 10 point.
3. When you have decided on the corrections to your article, select the NOTES tool from the Acrobat toolbox and click in the margin next to the text to be changed.
4. Enter your corrections into the NOTES text box window. Be sure to clearly indicate where the correction is to be placed and what text it will effect. If necessary to avoid confusion, you can use your TEXT SELECTION tool to copy the text to be corrected and paste it into the NOTES text box window. At this point, you can type the corrections directly into the NOTES text box window. **DO NOT correct the text by typing directly on the PDF page.**
5. Go through your entire article using the NOTES tool as described in Step 4.
6. When you have completed the corrections to your article, go to File/Export/Annotations (in Acrobat 4.0) or File/Export/Notes (in Acrobat 3.0). Save your NOTES file to a place on your harddrive where you can easily locate it. **Name your NOTES file with the article number assigned to your article in the original softproofing e-mail message.**
7. **When closing your article PDF be sure NOT to save changes to original file.**
8. To make changes to a NOTES file you have exported, simply re-open the original PDF proof file, go to File/Import/Notes and import the NOTES file you saved. Make changes and re-export NOTES file keeping the same file name.
9. When complete, attach your NOTES file to a reply e-mail message. Be sure to include your name, the date, and the title of the journal your article will be printed in.